In two large, open-label studies, 2697 cancer patients receiving non-platinum chemotherapy were included, 1895 with solid tumours (683 breast, 260 lung, 174 gynaecological, 300 gastro-intestinal, and 478 other tumour types) and 802 with haematological malignancies.
Kahes suures avatud uuringus osales 2697 vähihaiget, kes said plaatinat mittesisaldavat kemoteraapiat, 1895 soliidtuumoriga (683 rinna -, 260 kopsu -, 174 günekoloogilise, 300 gastrointestinaalse, 478 teise kasvajaga) ja 802 hematoloogilise vähiga.